Jubilant Pharmova Limited Approves Grant of 2,07,003 Stock Options and Units
Jubilant Pharmova Limited has approved the grant of 2,07,003 Stock Options, Restricted Stock Units (RSUs), and Performance Stock Units (PSUs) to eligible employees. The approval was granted by the members of the Nomination, Remuneration and Compensation Committee through a circular resolution passed on July 16, 2026.The allocation is part of the Jubilant Pharmova Employees Stock Option Plan 2018. The scheme adheres to the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
Grant Details and Pricing Structure
The grant covers a total of 2,07,003 equity shares with a face value of Re. 1 each. The pricing formula for the exercise of these units varies based on the category:| Category | Number of Units | Exercise Price |
|---|---|---|
| RSU/PSU | 1,81,570 | Re. 1 each (Face Value) |
| Stock Options | 25,433 | Rs. 974.45 each |
Vesting and Exercise Timeline
The vesting of these units is subject to the fulfillment of pre-vesting conditions. The schedule for different units is structured as follows:| Unit Type | Quantity | Vesting Criteria |
|---|---|---|
| RSU (Re. 1) | 23,102 | 3 years from date of grant based on performance |
| Stock Units (Rs. 974.45) | 25,433 | Year 1: 20%, Year 2: 30%, Year 5: 50% |
| PSUs (Re. 1) | 1,58,468 | Shall vest on April 01, 2029 |
The 1,81,570 Stock Options, RSUs, and PSUs are exercisable within a maximum period of 1 year from the date of vesting. The 25,433 Stock Options can be exercised within a maximum period of 8 years from the date of grant.
Key Terms of the Plan
The vesting of options is subject to a minimum vesting period of 1 year and a maximum vesting period of 5 years from the date of grant, in accordance with the Jubilant Pharmova Employees Stock Option Plan 2018.JUBLPHARMA Stock Price Movement
Jubilant Pharmova Limited shares today slipped by 0.53% to settle at ₹1,020.70. The stock saw a trading volume of 278,981 shares as it retreated from the day's high of ₹1,042.00.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.